重组人表皮生长因子治疗外伤性角膜上皮缺损

目的探讨重组人表皮生长因子(recombinant human epidermal growth factor,rhEGF)滴眼液治疗外伤性角膜上皮缺损的临床效果。方法观察100例外伤性角膜上皮缺损病例,随机分成治疗组50例和对照组50例,治疗组采用重组人表皮生长因子滴眼液滴入结膜囊,每日4次,每次1～2滴;对照组采用0.3%妥布霉素滴眼液滴入结膜囊,每日4次,每次1～2滴。滴眼后3d、6d观察角膜上皮缺损修复情况。结果滴眼3d和6d,rhEGF治疗组外伤性角膜上皮缺损的治疗率均高于对照组,经χ2检验,治疗组与对照组在滴眼后3d、6d差别有高度显著性(P<0.01)。结论重组人表皮生长因子(rhEGF)能够特异性地和角膜上皮细胞及内皮细胞受体相结合,很好地促进角膜上皮细胞的再生和修复,缩短病程,是一种治疗外伤性角膜上皮缺损的有效方法。

Clinical Effect of Recombinant Human Epidermal Growth Factor on Traumatic Corneal Epithelial Defect

Objective To evaluate the clinical effect of recombinant human epidermal growth factor(rhEGF) eye drops on traumatic corneal epithelial defect(TCED). Methods Total 100 cases with TCED were randomly divided into two groups:50 were treated by rhEGF eye drops,50 were treated by 0.3% Tobramycin eye drops.Corneal epithelial defect restoration were observed on 3 days and 6 days after trearment.Results The effect of rhEGF eye drops was prior to that of Tobramycin eye drops in TCED.The difference was significant between two group(P<0.01).Conclusion rhEGF eye drops can improve the healing of TCED effectively.